TerminatedPhase 4

Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses

Stopped: Terminated early due to lack of resources.

5 participantsStarted 2016-12-20

Plain-language summary

ACTHAR is a FDA approved drug for MS relapses. The purpose of the study is to examine the efficacy of this agent in improving relapses as measured by advanced MRI and laboratory techniques: 1. Advanced serial MRI studies on patients during and after an acute MS relapse. MRI will be performed at baseline, 1 month after the 1st dose of ACTHAR, and months 3, 6, and 12. ACTHAR will be administered for 10 days. Patients will start ACTHAR within 48 hours of relapse assessment. 2. Serial immune assays on patients during and after an acute MS relapse. Serum and blood samples with be collected at baseline, last day of ACTHAR (day 10 of therapy), 1 month post 1st dose, and months 3 and 6.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age \> 18 * undergoing a clinical relapse and associated MRI active lesion Exclusion Criteria: * Recent infection, any * use of any glucocorticoid 30 days prior to enrollment * unable to consent

What they're measuring

Change in T1 Lesion Relaxation Time

Timeframe: 12 month after the completion of intervention

Trial details

NCT IDNCT03021317

SponsorUniversity of Chicago

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-10-07

Results submitted2023-05-10

View on ClinicalTrials.gov More Multiple Sclerosis trials